Positive results - Phase 1B trial of possible MS drug AZ01
Posted: Wed Oct 19, 2011 2:19 am
Allozyne, Inc. announced today positive initial results from its multiple ascending dose (MAD) phase IB trial for its lead product candidate, AZ01, a clinical stage, PEGylated form of human interferon beta-1b for the treatment of relapsing-remitting multiple sclerosis (RRMS).
"We are very encouraged by the MAD study results, which demonstrate AZ01's potential for monthly dosing. AZ01 has the potential to fill an unmet need for MS patients who continue to place high priority on safe, convenient and effective treatment options for this chronic and debilitating disease," said Meenu Chhabra, Allozyne's CEO. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/3055